Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $32.49 USD
Change Today -0.12 / -0.37%
Volume 72.8K
HAE On Other Exchanges
As of 1:06 PM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

haemonetics corp/mass (HAE) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/27/15 - $45.43
52 Week Low
10/6/15 - $29.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for HAEMONETICS CORP/MASS (HAE)

Related News

No related news articles were found.

haemonetics corp/mass (HAE) Related Businessweek News

No Related Businessweek News Found

haemonetics corp/mass (HAE) Details

Haemonetics Corporation designs, manufactures, and markets blood management solutions. The company operates through North America Plasma, North America Blood Center and Hospital, Europe, Asia Pacific, and Japan segments. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components in the lab; and manual collection, filtration, and processing products. The company also offers hospital products comprising TEG thrombelastograph hemostasis analyzer systems that measure a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver systems for cardiovascular surgeries; and OrthoPAT surgical blood salvage systems for orthopedic procedures. In addition, it provides IMPACT Online blood management portal to monitor the results of its new blood management practices; SafeTrace Tx that manages blood product inventory and transfusions, and performs patient cross-matching; BloodTrack to manage tracking and control of blood products from the hospital blood center; and SafeTrace and El Dorado Donor donation and blood unit management systems, as well as Hemasphere, Donor Doc, and e-Donor software solutions. The company markets and sells its products to bio-pharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

3,383 Employees
Last Reported Date: 05/22/15
Founded in 1971

haemonetics corp/mass (HAE) Top Compensated Officers

Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $478.3K
Chief Operating Officer
Total Annual Compensation: $401.9K
Executive Vice President of Global Quality an...
Total Annual Compensation: $717.3K
Chief Science & Technology Officer
Total Annual Compensation: $441.0K
Compensation as of Fiscal Year 2015.

haemonetics corp/mass (HAE) Key Developments

Haemonetics Provides Earnings Guidance for the Second Quarter Ended September 26, 2015; Revises Earnings Guidance for the Full Fiscal Year 2016

Haemonetics provided earnings guidance for the second quarter ended September 26, 2015. The company announced that based on preliminary information, it expects to report revenue of $220 million and adjusted earnings approximating $0.40 per diluted share for its second fiscal 2016 quarter ended September 26, 2015. The company has also revised its previously-issued revenue and adjusted earnings guidance for the full fiscal year 2016. Revenue is now expected to be within the range of $910 million to $920 million, representing nil to 1% growth, which is below previous guidance of 4% to 6% growth. Fiscal year 2016 adjusted earnings guidance is revised to a range of $1.65 - $1.75 per share, which is below the previous guidance range of $1.98 - $2.08 per share.

Haemonetics Corporation Announces Management Changes

Haemonetics Corporation announced that Brian Concannon has resigned from his role as President and Chief Executive Officer and as a Director to pursue other opportunities, effective immediately. In connection with Mr. Concannon's resignation, Ronald Gelbman, a member of Haemonetics' Board of Directors, has been appointed as Interim CEO. To facilitate and ensure a seamless transition, Mr. Concannon will remain with the Company through October 31. Mr. Gelbman, joined the Haemonetics Board in 2000. Mr. Gelbman retired from Johnson & Johnson in April 2000, after serving in a variety of senior executive roles including as a member of the executive committee and as Worldwide Chairman of the Pharmaceuticals, Diagnostics and Health Systems Groups. He is currently a member of several boards, including SunTrust Southwest Florida Board of Advisors, and is a member of the Board of Trustees at the Out-of-Door Academy College Preparatory School.

Susan Hanlon, Vice President, Finance and Principal Accounting Officer to Leave Haemonetics Corporation

On September 3, 2015, Haemonetics Corporation and Susan Hanlon mutually agreed that Ms. Hanlon will leave Haemonetics to pursue other professional opportunities once her successor has been identified and successful transition of her responsibilities is completed. Ms. Hanlon has agreed to continue in her current capacity as Vice President, Finance and the company's principal accounting officer until that time.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HAE:US $32.49 USD -0.12

HAE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fresenius SE & Co KGaA €57.28 EUR -0.18
Medtronic PLC $73.20 USD +0.19
Terumo Corp ¥3,340 JPY -15.00
View Industry Companies

Industry Analysis


Industry Average

Valuation HAE Industry Range
Price/Earnings 82.3x
Price/Sales 1.8x
Price/Book 2.1x
Price/Cash Flow 80.5x
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAEMONETICS CORP/MASS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at